116 related articles for article (PubMed ID: 38650161)
1. The tumor suppressor effect of miRNA 200-c-3p on A549 non-small cell lung cancer cell line is associated with down-regulation of programmed cell death ligand 1; an immune-check point mechanism.
Ezzat S; Magda I Mohamad ; Manal Basyouni Ahmed ; Sara Elsayed Abdelrahman ; Nesma Hussein Abdel Hay ; Nashwa El-Khazragy ; Maha Imam Ismail
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):13-21. PubMed ID: 38650161
[TBL] [Abstract][Full Text] [Related]
2. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
3. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis.
Hao XZ; Yang K
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7399-7407. PubMed ID: 31539127
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
Wei S; Wang K; Huang X; Zhao Z; Zhao Z
Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
[TBL] [Abstract][Full Text] [Related]
7. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated
Sui J; Zhao Q; Zhang Y; Liang G
DNA Cell Biol; 2022 Mar; 41(3):319-329. PubMed ID: 35244469
[TBL] [Abstract][Full Text] [Related]
10. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis.
Dong Z; Liu H; Zhao G
Cancer Biother Radiopharm; 2020 Jun; 35(5):351-361. PubMed ID: 32202941
[No Abstract] [Full Text] [Related]
12. miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.
Hu C; Zou Y; Jing LL
J Biosci; 2020; 45():. PubMed ID: 32345774
[TBL] [Abstract][Full Text] [Related]
13. MiR-542-3p exerts tumor suppressive functions in non-small cell lung cancer cells by upregulating FTSJ2.
Liu B; Li J; Zheng M; Ge J; Li J; Yu P
Life Sci; 2017 Nov; 188():87-95. PubMed ID: 28866101
[TBL] [Abstract][Full Text] [Related]
14. MiR-323-3p Targeting Transmembrane Protein with EGF-Like and 2 Follistatin Domain (TMEFF2) Inhibits Human Lung Cancer A549 Cell Apoptosis by Regulation of AKT and ERK Signaling Pathways.
Fan JM; Zheng ZR; Zeng YM; Chen XY
Med Sci Monit; 2020 Feb; 26():e919454. PubMed ID: 32009129
[TBL] [Abstract][Full Text] [Related]
15. Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
Bian WG; Zhou XN; Song S; Chen HT; Shen Y; Chen P
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):649-659. PubMed ID: 30720173
[TBL] [Abstract][Full Text] [Related]
16. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
Jiang K; Zou H
Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
[TBL] [Abstract][Full Text] [Related]
17. miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.
Liu F; Wang X; Li J; Gu K; Lv L; Zhang S; Che D; Cao J; Jin S; Yu Y
Cell Prolif; 2015 Oct; 48(5):582-92. PubMed ID: 26250586
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
19. MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer.
Lu YJ; Liu RY; Hu K; Wang Y
Tumour Biol; 2016 Sep; 37(9):12685-12695. PubMed ID: 27448300
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
